DSIP
A 9-amino-acid neuropeptide originally isolated from sleeping rabbit brain, studied for effects on sleep architecture, stress response, and pain.
Molecular Structure
Amino Acid Sequence
Molecular Formula
Molecular Weight
Half-Life
CAS Number
What is DSIP?
Delta Sleep-Inducing Peptide (DSIP) was originally isolated by Schoenenberger and Monnier in 1974 from the cerebral venous blood of rabbits during electrically-induced sleep. Initial research suggested the peptide promoted delta-wave (slow-wave) sleep when administered to recipient animals, prompting the name and substantial research interest in sleep physiology. The compound is found in various tissues including brain, gastrointestinal tract, and peripheral organs across multiple species.
DSIP is notable in research for the breadth of effects observed across multiple physiological systems despite remaining mechanistically enigmatic after decades of study. The proposed sleep-promoting effects have been difficult to replicate consistently, and the specific receptor for DSIP has not been definitively identified. Research has documented effects on sleep architecture, stress response, pain modulation, and hormone regulation, though the precise molecular mechanisms remain incompletely characterized. The peptide has not advanced to formal clinical development but continues to be studied in sleep biology and stress research contexts.
Mechanism of action
DSIP’s mechanisms of action have been investigated across multiple pathways:
- Sleep architecture effects: Research has examined effects on sleep quality, particularly slow-wave (delta) sleep enhancement, though findings have been variable across studies.
- Stress response modulation: Studies have suggested anti-stress effects with modulation of cortisol and other stress markers, with some research showing improvements in stress-related behavioral measures in animal models.
- Pain modulation: Research has examined analgesic and pain-modulating effects in various models, with findings suggesting potential interactions with endogenous opioid pathways.
- Receptor identification challenges: Despite extensive research, the specific receptor mediating DSIP’s effects has not been definitively identified, complicating mechanistic characterization.
- Cross-blood-brain-barrier transport: Studies have documented passage of DSIP across the blood-brain barrier, supporting central nervous system effects following peripheral administration.
These pathways are characterized primarily in rodent models with mixed findings across studies.
Research applications
DSIP has been investigated across several research domains, with the most active areas including:
- Sleep research: The most prominent research application has examined effects on sleep quality and slow-wave sleep enhancement, though replication of the original 1970s findings has been inconsistent across subsequent studies.
- Stress response research: Studies have suggested anti-stress effects with modulation of cortisol and behavioral measures of stress resilience, with research interest in applications for stress-related conditions.
- Pain research: Research has examined analgesic and pain-modulating effects in various preclinical models, with some findings suggesting interactions with endogenous opioid systems.
- Alcohol withdrawal research: Early Russian research examined DSIP in alcohol withdrawal protocols, with findings suggesting potential effects on withdrawal-associated symptoms and stress markers.
- Hormone regulation research: Studies have documented effects on various hormonal systems including growth hormone, luteinizing hormone, and corticotropin-releasing hormone pathways.
This compound is intended for laboratory research use only. It has not been approved for human therapeutic use by any regulatory agency.
Storage & reconstitution
In its lyophilized form, DSIP tolerates ambient temperatures during shipping but should be stored long-term at -20°C, protected from light. Properly stored lyophilized peptide remains stable for 24 months or longer.
Once reconstituted with bacteriostatic water for injection, DSIP solutions should be stored refrigerated at 2-8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which can degrade peptide structure and reduce activity.
Visual inspection should be performed before each use. The reconstituted solution should be clear and colorless. Reject any solution that appears cloudy, discolored, or contains visible particulate matter.
For step-by-step reconstitution calculations, see our reconstitution calculator.
For laboratory research use only. The compound described on this page is intended exclusively for in vitro research and laboratory experimentation by qualified researchers and is not for human or veterinary use. It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by the FDA, Health Canada, EMA, or any other regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. The information provided on this page is for educational and reference purposes only and does not constitute medical advice. By accessing this content you confirm that you are a qualified researcher purchasing for legitimate laboratory purposes.